Physician profile
Lainie J Hurst
NPI 1013098136
$2,123.22
in general payments reported to CMS, 2019-2025
16 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $142 · 2021: $141 · 2022: $387 · 2023: $327 · 2024: $414 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.47 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $650.15 | 2020-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $442.39 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $349.17 | 2019-2025 | Mounjaro, Zepbound |
| Currax Pharmaceuticals LLC | $135.03 | 2022-2025 | Nexletol, Contrave |
| Dexcom, INC. | $123.23 | 2023 | Dexcom G6 Transmitter |
| Radius Health, INC. | $102.07 | 2023-2024 | Tymlos |
| Mannkind Corporation | $74.89 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $73.03 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Madrigal Pharmaceuticals | $56.15 | 2025 | Rezdiffra |
| Abbott Laboratories | $23.66 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.90 | 2019 | |
| Insulet Corporation | $17.20 | 2019 | |
| Genentech USA, INC. | $16.13 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.08 | 2022 | |
| Ibsa Pharma INC. | $13.24 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lainie Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.